Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma-Reference-Cited by-同舟云学术

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Published:2013-06-06 Issue:23 Volume:121 Page:4753-4757
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Usmani Saad Z.¹,Sawyer Jeffrey¹,Rosenthal Adam²,Cottler-Fox Michele¹,Epstein Joshua¹,Yaccoby Shmuel¹,Sexton Rachael²,Hoering Antje²,Singh Zeba¹,Heuck Christoph J.¹,Waheed Sarah¹,Chauhan Nabeel¹,Johann Donald¹,Abdallah Al-Ola¹,Muzaffar Jameel¹,Petty Nathan¹,Bailey Clyde¹,Crowley John²,van Rhee Frits¹,Barlogie Bart¹

Affiliation:

1. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, AR; and

2. Cancer Research and Biostatistics, Seattle, WA

Abstract

Key Points MDS-CAs were observed in 11% of 1080 patients and often preceded clinical MDS/acute leukemia. Risk factors for MDS-type cytogenetic abnormalities included immuno-modulatory drugs, older age, male gender, and low CD34 dose (<5 million/kg) given with first transplant.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/23/4753/1366166/4753.pdf

Reference20 articles.

1. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma.;Attal;N Engl J Med,2012

2. Lenalidomide after stem-cell transplantation for multiple myeloma.;McCarthy;N Engl J Med,2012

3. Continuous lenalidomide treatment for newly diagnosed multiple myeloma.;Palumbo;N Engl J Med,2012

4. Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.;Usmani;Blood,2012

5. Cytogenetically defined myelodysplasia after melphalan-based autotransplantation for multiple myeloma linked to poor hematopoietic stem-cell mobilization: the Arkansas experience in more than 3,000 patients treated since 1989.;Barlogie;Blood,2008

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation;Cancers;2024-03-11

2. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation;Transplantation and Cellular Therapy;2024-02

3. Small myeloid subclones are present at diagnosis of multiple myeloma in patients who develop secondary myelodysplastic syndromes;Haematologica;2023-10-19

4. Impact of second primary malignancy post–autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis;Blood Advances;2023-06-15

5. The emerging importance and evolving understanding of clonal hematopoiesis in multiple myeloma;Seminars in Oncology;2022-02